Total Payments
$27,998
2024 Payments
$533.27
Companies
17
Transactions
98
Medicare Patients
7,515
Medicare Billing
$2.5M
Payment Breakdown by Category
Research$25,389 (90.7%)
Food & Beverage$2,609 (9.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25,389 | 6 | 90.7% |
| Food and Beverage | $2,609 | 92 | 9.3% |
Payments by Type
Research
$25,389
6 transactions
General
$2,609
92 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $25,805 | 31 | $0 (2021) |
| ABBVIE INC. | $349.64 | 14 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $346.90 | 7 | $0 (2021) |
| Genentech USA, Inc. | $316.72 | 13 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $213.28 | 7 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $188.09 | 7 | $0 (2024) |
| Coherus Biosciences Inc. | $141.93 | 4 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $124.06 | 2 | $0 (2017) |
| EyePoint Pharmaceuticals US, Inc. | $104.84 | 1 | $0 (2022) |
| Astellas Pharma US Inc | $89.23 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $533.27 | 18 | Regeneron Healthcare Solutions, Inc. ($132.60) |
| 2023 | $545.38 | 18 | Apellis Pharmaceuticals, Inc. ($117.84) |
| 2022 | $434.80 | 16 | Genentech USA, Inc. ($126.65) |
| 2021 | $211.99 | 8 | Allergan, Inc. ($104.71) |
| 2020 | $74.07 | 4 | Allergan, Inc. ($74.07) |
| 2019 | $189.51 | 8 | Bausch & Lomb, a division of Bausch Health US, LLC ($116.28) |
| 2018 | $3,252 | 15 | Allergan Inc. ($2,943) |
| 2017 | $22,756 | 11 | Allergan Inc. ($22,610) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: OPTOMETRY | ||||||
| 10/30/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: EYE CARE | ||||||
| 10/15/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: OPTOMETRY | ||||||
| 10/15/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: OPTOMETRY | ||||||
| 10/09/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $36.32 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/17/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $34.38 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $65.96 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/10/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: EYE CARE | ||||||
| 06/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/02/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Ophthalmology | ||||||
| 04/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $30.39 | General |
| Category: EYE CARE | ||||||
| 04/02/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/26/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $32.47 | General |
| Category: Ophthalmology | ||||||
| 03/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $34.25 | General |
| Category: Ophthalmology | ||||||
| 02/07/2024 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $36.55 | General |
| Category: Ophthalmology | ||||||
| 01/30/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: EYE CARE | ||||||
| 12/12/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/09/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $54.18 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $30.04 | General |
| Category: Ophthalmology | ||||||
| 10/18/2023 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $41.90 | General |
| Category: Ophthalmology | ||||||
| 10/05/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $33.04 | General |
| 10/03/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: EYE CARE | ||||||
| 09/26/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $29.26 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $20,135 | 3 |
| Phase 2 - Evaluation of Abicipar Pegol in Patients with nAMD 1771-201-008 | Allergan Inc. | $2,841 | 2 |
| Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $2,413 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,935 | 10,777 | $2.5M | $739,688 |
| 2022 | 15 | 1,705 | 5,054 | $1.8M | $548,034 |
| 2021 | 17 | 1,992 | 5,729 | $2.0M | $613,782 |
| 2020 | 13 | 1,883 | 5,670 | $2.0M | $602,702 |
Total Patients
7,515
Total Services
27,230
Medicare Billing
$2.5M
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 37 | 314 | $628,000 | $210,120 | 33.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 28 | 4,320 | $315,360 | $124,673 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 520 | 1,454 | $189,020 | $89,783 | 47.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 203 | 965 | $530,750 | $78,075 | 14.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 12 | 326 | $146,700 | $59,041 | 40.2% |
| 92134 | Imaging of retina | Office | 2023 | 423 | 1,495 | $209,300 | $42,596 | 20.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 12 | 285 | $78,375 | $34,303 | 43.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 123 | 442 | $87,500 | $29,315 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 192 | 264 | $58,080 | $21,985 | 37.9% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 18 | 18 | $55,080 | $15,251 | 27.7% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 21 | 32 | $73,600 | $8,203 | 11.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 82 | 88 | $22,000 | $7,885 | 35.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $20,075 | $7,670 | 38.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 71 | 103 | $10,600 | $4,610 | 43.5% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Facility | 2023 | 11 | 11 | $11,000 | $2,548 | 23.2% |
| 92250 | Photography of the retina | Office | 2023 | 63 | 66 | $9,900 | $1,822 | 18.4% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 21 | 26 | $3,770 | $1,401 | 37.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 25 | 495 | $1,002 | $408.89 | 40.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 37 | 382 | $764,000 | $274,009 | 35.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 522 | 1,382 | $179,660 | $85,608 | 47.6% |
| 67028 | Injection of drug into eye | Office | 2022 | 169 | 772 | $424,600 | $61,016 | 14.4% |
| 92134 | Imaging of retina | Office | 2022 | 390 | 1,216 | $170,240 | $34,823 | 20.5% |
| 67041 | Removal of membrane of retina | Facility | 2022 | 29 | 29 | $88,740 | $25,146 | 28.3% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 111 | 437 | $43,700 | $22,433 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 134 | 164 | $36,080 | $13,264 | 36.8% |
About Dr. Richard Culbert, MD
Dr. Richard Culbert, MD is a Ophthalmology healthcare provider based in Midland, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881663995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Culbert, MD has received a total of $27,998 in payments from pharmaceutical and medical device companies, with $533.27 received in 2024. These payments were reported across 98 transactions from 17 companies. The most common payment nature is "" ($25,389).
As a Medicare-enrolled provider, Culbert has provided services to 7,515 Medicare beneficiaries, totaling 27,230 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Midland, TX
- Active Since 03/14/2006
- Last Updated 02/10/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1881663995
Products in Payments
- OZURDEX (Drug) $717.91
- Vabysmo (Drug) $190.07
- Cimerli (Biological) $174.40
- LOTEMAX SM (Drug) $168.27
- Syfovre (Drug) $152.09
- VYZULTA (Drug) $110.48
- YUTIQ (Drug) $104.84
- EYLEA HD (Biological) $102.28
- LOTEMAX GEL (Drug) $101.77
- SUSVIMO (Drug) $100.91
- EYLEA (Biological) $88.38
- Rhopressa (Drug) $82.30
- IHEEZO (Drug) $74.36
- ILUVIEN (Drug) $54.18
- Humira (Biological) $48.16
- LOTEMAX (Drug) $36.09
- EYLEA AFLIBERCEPT INJECTION (Biological) $22.62
- BESIVANCE (Drug) $22.29
- LUXTURNA (Biological) $20.42
- Stellaris (Device) $19.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Midland
Harshad Shah, Md,Pa, MD,PA
Ophthalmology — Payments: $3,329
Ophthalmology $3,329
Dr. Gerardo Escobedo, Do, DO
Ophthalmology — Payments: $2,832
Ophthalmology $2,832
Dr. Ronald Ingram, Pa, PA
Ophthalmology — Payments: $1,226
Ophthalmology $1,226
Dr. James Jackson, M.d, M.D
Ophthalmology — Payments: $43.21
Ophthalmology $43.21
Dr. Christopher Bigelow, M.d, M.D
Ophthalmology — Payments: $19.40
Ophthalmology $19.40
Linferd Linabery, M.d, M.D
Ophthalmology
Ophthalmology